Advisory – Fundraising
Protect your company against employee error and report fraud through advanced general ledger analytics. The GLAnalytics software solution is a cloud-based, highly secure, proactive employee error and fraud detection system. Features include:
- Modules for active monitoring of payroll, accounts payable, accounts receivable and general journal entries
- Easy-to-use, refined user experience
- Highly secure interface utilizing the best available encryption technology
- Algorithms that scour your payroll, accounts payable, accounts receivable and general journal entry databases to highlight and report on a wide variety of anomalies where human intervention and further review are suggested.
Advisory – Business Strategy, Fundraising and Product Development
xSensa Labs’ mission is to help people with brain training. The goal is to invoke mental resources on demand, whether to enhance mental agility, reduce stress or increase creativity.
Its first mobile app, DeepWave, was envisioned as a much-needed everyday tool that changes the way people handle stress and mental fatigue.
Unlike brain games which target narrow cognitive skills, DeepWave’s comprehensive training suite enhances a broad range of regenerative brain functions. DeepWave’s immersive visual and auditory training provides continuous feedback from the user's brain signals. It communicates with wearable sensors and is completely non-invasive. By playing simple and intuitive games, users train to achieve beneficial brain states. It is like a gym for the brain: it takes discipline and effort.
Mastering self is the ultimate reward.
Chief Revenue Officer – Interim CRO
Riwi.com is a global survey technology company. RIWI’s patented Random Domain Intercept Technology (RDIT™) is the only all-device technology capable of randomly intercepting online survey respondents in every Web-enabled country and territory in the world. RIWI completed a C$1.6 million private placement in March 2017. The funds will allow RIWI to fully scale up its operations. The Interim CRO management effort and guidance role applied to restructuring and streamlining sales process activities. The mandate included revamping the commercialization and marketing strategies, and recruiting and leading the team of executives responsible for RIWI’s marketing and sales both in Canada and the USA.
Corporate Business Development Leader
The ACIC Group is a full-service pharmaceutical and fine chemicals company that manufactures and provides clients and partners with active pharmaceutical ingredients, contract manufacturing services, process development and optimization, clinical services and finished dosage forms, from CGMP, FDA-inspected facilities. Over the past 40 years, ACIC has established itself as a global player in the pharmaceutical and fine chemicals business, from molecule to market.
Methapharm, a specialty pharmaceutical division of the ACIC Group, focuses on the acquisition, licensing and promotion of healthcare products in North America. The company markets proprietary products and distributes products from partner companies. In addition to its presence in the USA and Canada, the ACIC Group also has a European affiliate to coordinate international licensing opportunities.
The Corporate Business Development Leader led the team in creating a five-year growth plan for the ACIC Group. The Corporate Business Development Leader assisted in increasing the professionalization of Methapharm’s management team, including the hiring of a senior pharmaceutical executive as its President/CEO. The mandate also included the development of new business opportunities for ACIC’s core clients in the USA – Amneal Pharmaceuticals and Adello Biologics.
International Expansion Advisor
The International Expansion Advisor led the business development of North American companies in Brazil. This advisory role included market potential assessment – gauging the size and attractiveness of demand, as well as the intensity of competition from local players for each client business. The Advisor participated in the identification and selection of significant business opportunities to export products to or establish a local presence in the country. For Adello Biologics the mandate included the co-development with Brazilian companies of private-public partnerships for selling biosimilars to the federal government. Finally, the advisory mandate included the identification of potential acquisition targets, evaluating M&As as an alternative to greenfield operations.
Adello Biologics, formerly known as Therapeutic Proteins International, LLC, is an innovative, U.S.-based, pure-play biosimilar company focused on developing recombinant proteins and antibody products for major regulated markets and strategic markets globally. Adello Biologics has utilized its proprietary, single-use technology platform, MayaBio®, to build a robust pipeline of biosimilar candidates.
Amneal Pharmaceuticals is the seventh largest generic pharmaceutical manufacturer in the United States and the fastest-growing generic company globally, according to IMS Health. Amneal’s diversified portfolio includes high-quality complex dosage forms, such as liquids, topicals, transdermals, injectables and inhalation products.